阿托伐他汀钙在2型糖尿病合并冠心病治疗中的应用效果
|
摘要
目的探讨阿托伐他汀钙在2型糖尿病(T2DM)合并冠心病治疗中的应用效果。方法选取2015年1月至2016年8月我院收治的120例T2DM合并冠心病患者作为研究对象,按照入院治疗时间顺序分为观察组和对照组,各60例。对照组给予常规治疗,观察组在此基础上给予阿托伐他汀钙片治疗。比较两组患者总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、空腹血糖(FPG)、餐后血糖(PPG)、糖化血红蛋白(HbAlc)水平及心脑血管事件发生情况。结果治疗前,两组患者TC、TG、LDL-C、HDL-C、FPG、PPG、HbAlc水平比较,差异均无统计学意义(P>0.05);治疗后,观察组TC、TG、LDL-C、HDL-C水平均改善,且TC、TG、LDL-C、HDL-C水平明显优于对照组(P<0.05)。观察组治疗期间心脑血管事件总发生率为11.67%,低于对照组的31.67%(P<0.05)。结论在T2DM合并冠心病的治疗中,应用阿托伐汀钙可有效控制患者血脂水平,降低患者心脑血管事件发生风险。
Objective To investigate the application effect of atorvastatin calcium in the treatment of type 2 diabetesmellitus(T2DM) with coronary heart disease. Methods A total of 120 cases of T2 DM patients with coronary heart diseaseadmitted in our hospital from January 2015 to August 2016 were selected as the research objects and divided intoobservation group and control group according to the time sequence of admission, with 60 cases in each group. Thecontrol group was given routine treatment, and the observation group was treated with atorvastatin calcium tablets on thisbasis. The levels of total cholesterol(TC), triglyceride(TG), low density lipoprotein cholesterol(LDL-C), high densitylipoprotein cholesterol(HDL-C), fasting plasma glucose(FPG), postprandial plasma glucose(PPG), glycosylatedhemoglobin(HbAlc) and the incidence of cardiovascular and cerebrovascular events were compared between the twogroups. Results Before treatment, there were no significant differences in the levels of TC, TG, LDL-C, HDL-C, FPG,PPG and HbAlc between the two groups(P >0.05). After treatment, the levels of TC, TG, LDL-C and HDL-C in theobservation group improved, and the levels of TC, TG, LDL-C and HDL-C in the observation group were significantlybetter than those in the control group(P<0.05). The total incidence of cardiovascular and cerebrovascular events in theobservation group was 11.67%, which was lower than 31.67% in the control group(P<0.05). Conclusion In the treatmentof T2 DM with coronary heart disease, atorvastatin calcium can effectively control the blood lipid levels of patients andreduce the risk of cardiovascular and cerebrovascular events.
Objective To investigate the application effect of atorvastatin calcium in the treatment of type 2 diabetesmellitus(T2DM) with coronary heart disease. Methods A total of 120 cases of T2 DM patients with coronary heart diseaseadmitted in our hospital from January 2015 to August 2016 were selected as the research objects and divided intoobservation group and control group according to the time sequence of admission, with 60 cases in each group. Thecontrol group was given routine treatment, and the observation group was treated with atorvastatin calcium tablets on thisbasis. The levels of total cholesterol(TC), triglyceride(TG), low density lipoprotein cholesterol(LDL-C), high densitylipoprotein cholesterol(HDL-C), fasting plasma glucose(FPG), postprandial plasma glucose(PPG), glycosylatedhemoglobin(HbAlc) and the incidence of cardiovascular and cerebrovascular events were compared between the twogroups. Results Before treatment, there were no significant differences in the levels of TC, TG, LDL-C, HDL-C, FPG,PPG and HbAlc between the two groups(P >0.05). After treatment, the levels of TC, TG, LDL-C and HDL-C in theobservation group improved, and the levels of TC, TG, LDL-C and HDL-C in the observation group were significantlybetter than those in the control group(P<0.05). The total incidence of cardiovascular and cerebrovascular events in theobservation group was 11.67%, which was lower than 31.67% in the control group(P<0.05). Conclusion In the treatmentof T2 DM with coronary heart disease, atorvastatin calcium can effectively control the blood lipid levels of patients andreduce the risk of cardiovascular and cerebrovascular events.
引文
[1]邹月香,邓爱辉,钟瑶,等.2型糖尿病患者授权能力对自我管理行为的影响[J]中国护理管理,2013,13(1):43.
[2]金志萍,顾红英,倪小英,等.社区2型糖尿病老年患者个体化自我管理效果评估[J].上海预防医学,2018,30(2):120-125.
[3]王晓霞,鲜彤章,贾晓凡,等.2型糖尿病患者的心脑血管疾病影响因素的Nomogram分析[J].中国心血管杂,2017,22(1):43-48.
[4]杨晓芬,刘霞,马鹏飞.氯吡格雷抵抗对冠心病合并糖尿病患者PCI治疗后不良事件的影响[J].陕西医学杂志,2016,45(12):1679-1680.
[5]王文绢,董晶,任泽萍,等.糖尿病高危人群生活方式干预知识、态度、行为评价量表的效度、信度及可接受性评价[J].中华预防医学杂志,2016,50(7):584-588.
[6]徐为高.冠心病患者血清超敏C反应蛋白和同型半胱氨酸水平变化及临床意义[J].临床医学与实践,2018,31(11):1674-1676.
[7]张维明,梁宪宏,孟庆文.老年女性糖尿病合并冠心病血脂代谢异常分析[J].航空航天医学杂志,2012,23(9):1063-1064.
[8]吴秀英,李建中,郭建政,等.2型糖尿病合并冠心病的相关危险因素[J].中国老年学杂志,2012,32(20):4488-4489.
[9]葛均波,徐永健.内科学[M].8版.北京:人民卫生出版社,2013:762-766.
[10]李淑婷,徐佳莹,黄榕翀.阿托伐他汀钙药物依从性对冠心病患者心血管不良事件预后影响的荟萃分析[J].中华心血管病杂志2016,44(8):684-690.
[11]黄刚,罗贵全,唐川苏,等.不同强度阿托伐他汀对急性冠脉综合征患者高敏C反应蛋白的影响[J].四川生理科学杂志,2015,37(3)118-120.
[12]何旭春,郑宗富.阿托伐他汀治疗冠心病患者的疗效[J].中国老年学杂志,2015,35(22):6382-6383.
[13]孙正松,高冰,蔺静.心血管疾病治疗中阿托伐他汀钙药物的疗效[J].中西医结合心血管病电子杂志,2016,4(1):62-63.
[14]任霖,唐海燕.阿托伐他汀钙对冠心病合并2型糖尿病患者血浆骨桥蛋白及脂代谢的影响[J].宁夏医科大学学报,2012,34(12)1312-1314.
[15]胡景鲁.两种方案治疗2型糖尿病并冠心病不稳定心绞痛的成本-效果分析[J].糖尿病新世界,2015(1):97-98.
[16]刘丽华,罗培.冠心病合并2型糖尿病患者主要生理指标分析及阿托伐他汀钙的应用价值[J].现代中西医结合杂志,2015,24(16)1756-1758.
[2]金志萍,顾红英,倪小英,等.社区2型糖尿病老年患者个体化自我管理效果评估[J].上海预防医学,2018,30(2):120-125.
[3]王晓霞,鲜彤章,贾晓凡,等.2型糖尿病患者的心脑血管疾病影响因素的Nomogram分析[J].中国心血管杂,2017,22(1):43-48.
[4]杨晓芬,刘霞,马鹏飞.氯吡格雷抵抗对冠心病合并糖尿病患者PCI治疗后不良事件的影响[J].陕西医学杂志,2016,45(12):1679-1680.
[5]王文绢,董晶,任泽萍,等.糖尿病高危人群生活方式干预知识、态度、行为评价量表的效度、信度及可接受性评价[J].中华预防医学杂志,2016,50(7):584-588.
[6]徐为高.冠心病患者血清超敏C反应蛋白和同型半胱氨酸水平变化及临床意义[J].临床医学与实践,2018,31(11):1674-1676.
[7]张维明,梁宪宏,孟庆文.老年女性糖尿病合并冠心病血脂代谢异常分析[J].航空航天医学杂志,2012,23(9):1063-1064.
[8]吴秀英,李建中,郭建政,等.2型糖尿病合并冠心病的相关危险因素[J].中国老年学杂志,2012,32(20):4488-4489.
[9]葛均波,徐永健.内科学[M].8版.北京:人民卫生出版社,2013:762-766.
[10]李淑婷,徐佳莹,黄榕翀.阿托伐他汀钙药物依从性对冠心病患者心血管不良事件预后影响的荟萃分析[J].中华心血管病杂志2016,44(8):684-690.
[11]黄刚,罗贵全,唐川苏,等.不同强度阿托伐他汀对急性冠脉综合征患者高敏C反应蛋白的影响[J].四川生理科学杂志,2015,37(3)118-120.
[12]何旭春,郑宗富.阿托伐他汀治疗冠心病患者的疗效[J].中国老年学杂志,2015,35(22):6382-6383.
[13]孙正松,高冰,蔺静.心血管疾病治疗中阿托伐他汀钙药物的疗效[J].中西医结合心血管病电子杂志,2016,4(1):62-63.
[14]任霖,唐海燕.阿托伐他汀钙对冠心病合并2型糖尿病患者血浆骨桥蛋白及脂代谢的影响[J].宁夏医科大学学报,2012,34(12)1312-1314.
[15]胡景鲁.两种方案治疗2型糖尿病并冠心病不稳定心绞痛的成本-效果分析[J].糖尿病新世界,2015(1):97-98.
[16]刘丽华,罗培.冠心病合并2型糖尿病患者主要生理指标分析及阿托伐他汀钙的应用价值[J].现代中西医结合杂志,2015,24(16)1756-1758.